Aliases & Classifications for Eye Disease

Aliases & Descriptions for Eye Disease:

Name: Eye Disease 12 14
Disorder of Eye 69
Eye Diseases 42

Classifications:



Summaries for Eye Disease

Disease Ontology : 12 An eye and adnexa disease that is located in the eye.

MalaCards based summary : Eye Disease, also known as disorder of eye, is related to macular degeneration, age-related, 2 and exophthalmos, and has symptoms including eye manifestations, pain in or around eye and redness or discharge of eye. An important gene associated with Eye Disease is CACNA1F (Calcium Voltage-Gated Channel Subunit Alpha1 F), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Allograft rejection. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include eye, thyroid and testes, and related phenotypes are cardiovascular system and nervous system

Wikipedia : 71 This is a partial list of human eye diseases and... more...

Related Diseases for Eye Disease

Diseases related to Eye Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
id Related Disease Score Top Affiliating Genes
1 macular degeneration, age-related, 2 31.1 ABCA4 CACNA1F
2 exophthalmos 31.0 CXCL8 IL10 IL1B IL6 TNF
3 neuropathy 29.9 CXCL8 IL1B IL6 TNF
4 keratoconus 29.8 IL1B IL6 TNF
5 neovascular glaucoma 29.5 CCL2 CXCL8 IL6 TNF
6 rheumatoid arthritis 29.3 CCL2 CXCL8 IL10 IL1B IL6 TNF
7 fish-eye disease 12.2
8 aland island eye disease 12.2
9 bornholm eye disease 12.1
10 norum disease 11.3
11 ethylmalonic encephalopathy 11.2
12 superior limbic keratoconjunctivitis 10.8
13 myopia, x-linked 10.8
14 night blindness 10.7
15 familial lcat deficiency 10.7
16 ocular hypertension 10.7
17 cavitary optic disc anomalies 10.7
18 macular degeneration, age-related, 1 10.5
19 senior-loken syndrome-1 10.5
20 retinitis pigmentosa 10.5
21 usher syndrome 10.5
22 retinal disease 10.5
23 thyroiditis 10.4
24 intussusception 10.4 IL1B TNF
25 rhizomelic chondrodysplasia punctata 10.4 ARMS2 C2 CFB CFH
26 hand, foot and mouth disease 10.4 ARMS2 CFB CFH VEGFA
27 degenerative disc disease 10.4 IL6 TNF VEGFA
28 cone-rod dystrophy 17 10.4 ARMS2 CFB CFH VEGFA
29 autosomal dominant charcot-marie-tooth disease type 2 with giant axons 10.4 CACNA1F TNF
30 aortic coarctation 10.4 CFH IL6 TNF
31 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
32 vogt-koyanagi-harada disease 10.4 IL6 TNF VEGFA
33 oculomotor nerve paralysis 10.4 CXCL8 IL1B IL6
34 common peroneal nerve lesion 10.4 CXCL8 IL1B IL6
35 thymic neuroendocrine carcinoma 10.4 CXCL8 IL6 TNF
36 anal paget's disease 10.4 IL1B IL6 TNF
37 peeling skin syndrome 1 10.4 C2 CFB
38 conidiobolomycosis 10.4 CXCL8 IL10 TNF
39 human immunodeficiency virus infectious disease 10.4 IL1B IL6 TNF
40 tinea capitis 10.4 IL1B IL6 TNF
41 transient tic disorder 10.4 IL10 IL6 TNF
42 measles 10.4 IL1B IL6 TNF
43 dextrocardia 10.4 IL1B IL6 TNF
44 esophagus lymphoma 10.4 CXCL8 IL6 TNF
45 amyotrophic lateral sclerosis type 14 10.4 CXCL8 IL1B TNF
46 leukoplakia of vagina 10.4 IL6 TNF VEGFA
47 neonatal hypoxic and ischemic brain injury 10.4 CXCL8 IL10 IL6
48 plantar wart 10.4 CXCL8 IL10 TNF
49 mikulicz disease 10.4 IL1B IL6 TNF
50 cyclosporiasis 10.4 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Eye Disease:



Diseases related to Eye Disease

Symptoms & Phenotypes for Eye Disease

UMLS symptoms related to Eye Disease:


eye manifestations, pain in or around eye, redness or discharge of eye, pathological conditions, signs and symptoms, lid retraction, visual disturbance

MGI Mouse Phenotypes related to Eye Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 ABCA4 CFH IL10 IL1B IL6 LCAT
2 nervous system MP:0003631 9.9 PAX6 ROM1 TNF VEGFA ABCA4 CACNA1F
3 neoplasm MP:0002006 9.8 CYP1B1 IL10 IL1B IL6 PAX6 TNF
4 renal/urinary system MP:0005367 9.56 LCAT NPHP1 OAT PAX6 VEGFA CFB
5 vision/eye MP:0005391 9.44 ABCA4 CACNA1F CFH CYP1B1 IL10 IL6

Drugs & Therapeutics for Eye Disease

Drugs for Eye Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 792)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2 60142-96-3 3446
5
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
6
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
8
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
10
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 15307-86-5 3033
13
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 85721-33-1 2764
14
Ganciclovir Approved, Investigational Phase 4,Phase 2,Phase 1 82410-32-0 3454
15
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
16
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 9004-61-9 53477741 24759
17
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
18
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
19
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
20
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 5908-99-6, 51-55-8 174174
21
Glycerol Approved, Experimental Phase 4,Phase 2,Phase 3 56-81-5 753
22
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
23
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
24
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
25
Topiramate Approved Phase 4 97240-79-4 5284627
26
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
27
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 59-42-7 6041
28
Oxymetazoline Approved Phase 4,Phase 3,Phase 2,Phase 1 1491-59-4 4636
29
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 26839-75-8 33624 5478
30
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
31
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
33
Propylthiouracil Approved Phase 4,Phase 3 51-52-5 657298
34
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 137-58-6 3676
35
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
36
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2 59-66-5 1986
37
Pilocarpine Approved Phase 4,Phase 3 54-71-7, 92-13-7 5910
38
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
39
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
40
Minocycline Approved, Investigational Phase 4,Phase 2,Phase 1 10118-90-8 5281021
41
Brinzolamide Approved Phase 4,Phase 3,Phase 2 138890-62-7 68844
42
Dorzolamide Approved Phase 4,Phase 2,Phase 3,Phase 1 120279-96-1 3154 5284549
43
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
44
Ofloxacin Approved Phase 4,Phase 2,Phase 3,Phase 1 82419-36-1 4583
45
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 564-25-0 54671203
46
Tropicamide Approved Phase 4,Phase 3,Phase 2,Phase 1 1508-75-4 5593
47
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 124-94-7 31307
48
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
49
Cefazolin Approved Phase 4,Phase 3 25953-19-9 656510 33255
50
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130209-82-4 5282380 5311221

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Unknown status NCT01927406 Phase 4
2 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4
3 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4
4 Lipids of the Human Tear Film and Their Effect on Tear Stability Unknown status NCT00803452 Phase 4
5 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
6 Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery Unknown status NCT01229202 Phase 4
7 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
8 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252862 Phase 4
9 Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects Unknown status NCT01252849 Phase 4
10 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252888 Phase 4
11 Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose Unknown status NCT00347828 Phase 4
12 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
13 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
14 A New More Efficient Cycloplegia Scheme Unknown status NCT02177539 Phase 4
15 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4
16 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4
17 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
18 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
19 Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure Unknown status NCT00796198 Phase 4
20 A Intra-patient Comparison of Closed Loop and Plate Haptic Toric Intraocular Lenses Unknown status NCT02264457 Phase 4
21 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK Unknown status NCT01977807 Phase 4
22 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy Unknown status NCT00442312 Phase 4
23 Tear Film Evaluation After Phacoemulsification Unknown status NCT02238015 Phase 4
24 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4
25 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
26 Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty Unknown status NCT01444105 Phase 4
27 Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma Unknown status NCT01401088 Phase 4
28 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK Unknown status NCT02071576 Phase 4
29 Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism Unknown status NCT01628146 Phase 4
30 Multi Laser Platform Comparison Study for LASIK Unknown status NCT00770094 Phase 4
31 Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery Unknown status NCT00468429 Phase 4
32 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
33 A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia Unknown status NCT02112968 Phase 4
34 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4
35 Clinical Investigation of the Bi Flex M Multifocal IOL Unknown status NCT02338882 Phase 4
36 Ologen (OculusGen)-Glaucoma MMC Control Trial in India Unknown status NCT00449098 Phase 4
37 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
38 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4
39 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4
40 Saline Injection - Assisted Anesthesia in Eyelid Surgery Unknown status NCT01239498 Phase 4
41 Study of Myopia Prevention in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4
42 Choroidal Thickness in Glaucoma Patients and Healthy Controls Unknown status NCT01293474 Phase 4
43 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
44 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
45 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Unknown status NCT01296542 Phase 4
46 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4
47 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
48 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
49 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
50 The Effect of Education on Patient Compliance Unknown status NCT00376974 Phase 4

Search NIH Clinical Center for Eye Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: eye diseases

Genetic Tests for Eye Disease

Anatomical Context for Eye Disease

MalaCards organs/tissues related to Eye Disease:

39
Eye, Thyroid, Testes, Endothelial, T Cells, Bone, Retina

The Foundational Model of Anatomy Ontology organs/tissues related to Eye Disease:

18
The Eye

Publications for Eye Disease

Articles related to Eye Disease:

(show top 50) (show all 754)
id Title Authors Year
1
Peripheral Retinal Changes Associated withA Age-Related Macular Degeneration inA the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by theA Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group. ( 28089680 )
2017
2
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). ( 28079022 )
2017
3
Patients With Dry Eye Disease and Low Subbasal Nerve Density Are at High Risk for Accelerated Corneal Endothelial Cell Loss. ( 28060067 )
2017
4
Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease. ( 28058622 )
2017
5
Surgical outcomes of unilateral recession-resection for vertical strabismus in patients with thyroid eye disease. ( 28089937 )
2017
6
Assessment of the Tear Meniscus by Strip Meniscometry and Keratograph in Patients With Dry Eye Disease According to the Presence of Meibomian Gland Dysfunction. ( 28060066 )
2017
7
Conjunctival impression cytology evaluation of patients with dry eye disease using scleral contact lenses. ( 28089075 )
2017
8
Dataset of tear film cytokine levels in dry eye disease (DED) patients with and without HIV infection. ( 27942559 )
2017
9
Epidemiology of dry eye disease in Africa: The sparse information, gaps and opportunities. ( 28065724 )
2017
10
Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids? ( 28050807 )
2017
11
Clinical Characteristics, Mutation Spectrum, and Prevalence of A8land Eye Disease/Incomplete Congenital Stationary Night Blindness in Denmark. ( 28002560 )
2016
12
PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPEL-LINDAU EYE DISEASE. ( 26308528 )
2016
13
Unmet Needs and Future Directions in Inflammatory Eye Disease. ( 27070178 )
2016
14
Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease. ( 27181583 )
2016
15
Hypertensive eye disease: a review. ( 27990740 )
2016
16
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. ( 27055414 )
2016
17
Fish-eye disease: Another under-recognized cause of familial corneal opacification. ( 26854387 )
2016
18
A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 I1g/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (VismedAr) in Patients with Moderate Dry Eye Disease. ( 27614318 )
2016
19
Depression and anxiety in dry eye disease: a systematic review and meta-analysis. ( 27518547 )
2016
20
Structural Functional Associations of the Orbit in Thyroid Eye Disease: Kalman Filters to Track Extraocular Rectal Muscles. ( 27127330 )
2016
21
Two Patients with Dry Eye Disease Followed Up Using an Expression Assay of Ocular Surface Mucin. ( 27194990 )
2016
22
Perspective: A Critical Look at the Ancillary Age-Related Eye Disease Study 2: Nutrition and Cognitive Function Results in Older Individuals with Age-Related Macular Degeneration. ( 27184270 )
2016
23
Corneal permeability changes in dry eye disease: an observational study. ( 27177442 )
2016
24
In vivo ocular biomechanical compliance in thyroid eye disease. ( 27941044 )
2016
25
Relief From Dry Eye Disease. ( 27599324 )
2016
26
Predictors of Discordance between Symptoms and Signs in Dry Eye Disease. ( 28024826 )
2016
27
Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. ( 27521662 )
2016
28
Efficacy of a fixed combination of 0.09A % xanthan gum/0.1A % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial. ( 27645318 )
2016
29
Dry Eye Disease in Patients with Functioning Filtering Blebs after Trabeculectomy. ( 27032098 )
2016
30
The eye disease of Jean-Paul Sartre and its impact on his literary work. ( 27091424 )
2016
31
Effect of smoking on retrobulbar blood flow in thyroid eye disease. ( 27540833 )
2016
32
Lifestyle Determinants on Prevention and Improvement of Dry Eye Disease from the Perspective of Iranian Traditional Medicine. ( 27516671 )
2016
33
Evidence of seasonality and effects of psychrometry in dry eye disease. ( 27105776 )
2016
34
Repeatability and Reproducibility of Noninvasive Keratograph 5M Measurements in Patients with Dry Eye Disease. ( 27190639 )
2016
35
Customized Minimally Invasive Orbital Decompression Surgery Improves Lower Eyelid Retraction and Contour in Thyroid Eye Disease. ( 27997462 )
2016
36
Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. ( 27665213 )
2016
37
Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease. ( 27599688 )
2016
38
A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection. ( 27585367 )
2016
39
In Vivo Confocal Microscopy in Dry Eye Disease Associated With Chronic Graft-Versus-Host Disease. ( 27607414 )
2016
40
Comprehensive Review of the Literature on Existing Punctal Plugs for the Management of Dry Eye Disease. ( 27088009 )
2016
41
Surgical Responses of Medial Rectus Muscle Recession in Thyroid Eye Disease-Related Esotropia. ( 26796354 )
2016
42
Dataset of eye disease-related proteins analyzed using the unfolding mutation screen. ( 27922631 )
2016
43
Secret in the eyes - fish eye disease. ( 27512314 )
2016
44
Lifitegrast (Xiidra) for dry eye disease. ( 27552207 )
2016
45
Assessment of Transepidermal Water Loss From the Ocular Area in Dry Eye Disease. ( 27654410 )
2016
46
NRP1 function and targeting in neurovascular development and eye disease. ( 26923176 )
2016
47
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. ( 27055211 )
2016
48
Secondary malignancy following radiotherapy for thyroid eye disease. ( 27601944 )
2016
49
Prevalence of Childhood Blindness and Ocular Morbidity in a Rural Pediatric Population in Southern India: The Pavagada Pediatric Eye Disease Study-1. ( 27142419 )
2016
50
Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. ( 27515572 )
2016

Variations for Eye Disease

Expression for Eye Disease

Search GEO for disease gene expression data for Eye Disease.

Pathways for Eye Disease

Pathways related to Eye Disease according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 CCL2 CXCL8 IL10 IL1B IL6 TNF
2
Show member pathways
12.85 CXCL8 IL10 IL1B IL6 TNF VEGFA
3
Show member pathways
12.78 CCL2 CXCL8 IL1B IL6 TNF
4
Show member pathways
12.59 CCL2 IL10 IL1B IL6 TNF
5
Show member pathways
12.34 CCL2 CXCL8 IL1B IL6 TNF
6
Show member pathways
12.32 CCL2 IL1B IL6 TNF
7
Show member pathways
12.27 CXCL8 IL1B IL6 TNF
8 12.23 IL10 IL1B IL6 TNF
9
Show member pathways
12.19 CXCL8 IL1B IL6 TNF
10
Show member pathways
12.17 CXCL8 IL10 IL1B IL6 TNF
11 12.15 CXCL8 IL10 IL1B IL6 TNF VEGFA
12 12.09 CCL2 IL1B TNF VEGFA
13 12.02 CCL2 CXCL8 IL1B IL6 TNF
14 11.95 CCL2 IL1B IL6 TNF
15
Show member pathways
11.94 IL10 IL1B IL6 TNF
16 11.89 CXCL8 IL10 IL1B IL6 TNF
17 11.84 CCL2 CXCL8 IL1B IL6 TNF VEGFA
18 11.8 CXCL8 IL1B IL6
19 11.77 IL10 IL1B TNF
20 11.77 IL10 IL1B IL6 TNF
21 11.76 CCL2 CXCL8 IL10 IL1B IL6 TNF
22 11.75 CCL2 CXCL8 IL1B IL6 TNF VEGFA
23 11.7 IL10 IL6 TNF
24 11.63 C2 CFB CFH IL10
25 11.63 CCL2 CXCL8 IL1B IL6 TNF
26 11.61 CXCL8 IL1B IL6 TNF
27 11.61 C2 CXCL8 IL10 IL1B IL6 TNF
28
Show member pathways
11.6 CXCL8 IL1B IL6 TNF VEGFA
29 11.56 CXCL8 IL6 VEGFA
30 11.52 CYP1B1 TNF VEGFA
31 11.52 CYP1B1 IL1B TNF
32 11.52 CCL2 IL1B TNF
33 11.48 IL1B IL6 TNF
34 11.38 IL10 IL1B IL6 TNF
35 11.37 IL10 IL1B IL6 TNF
36 11.35 CCL2 CXCL8 IL6
37 11.31 IL1B IL6 TNF
38 11.29 IL1B IL6